Biotech, pharmaceutical and medical companies could catch a bit of a tailwind Thursday, after analysts at Evercore ISI initiated positive coverage on 14 stocks in the sector. Three notable calls center around BioMarin Pharmaceutical Inc  (BMRN) , AbbVie Inc (ABBV) and Regeneron Pharmaceuticals Inc (REGN) .

Analyst Josh Schimmer initiated coverage of Regeneron with an outperform rating and $605 price target. Based on Wednesday's closing price near $468, the price target implies about 30% from current levels. That's quite a bit of upside, especially considering REGN stock is up more than 25% since the end of April.

Schimmer also has a bullish outlook on BioMarin, which he slapped with an outperform rating and $100 price target. It implies about $17 a share of upside from its current price near $83, a gain of more than 20%.

Finally, Schimmer placed an outperform rating and $95 price target on AbbVie, which most recently closed near $70. The near-$25 per share of potential upside would represent a gain of more than 35%.

Other notable outperform ratings from Schimmer include Shire PLC (SHPG) , which received a $196 price target, Ionis Pharmaceuticals Inc (IONS) , which received a $65 price target, and GW Pharmaceuticals (GWPH) , which received a $154 price target.

More of What's Trending on TheStreet:

This article is commentary by an independent contributor. At the time of publication, the author had no positions in the stocks mentioned.

More from Markets

Dow Surges as Strong Earnings Push the Blue-Chip Index Higher, Nasdaq Rises 2%

Dow Surges as Strong Earnings Push the Blue-Chip Index Higher, Nasdaq Rises 2%

Is Uber Really Worth More Than GM, Ford and Fiat Combined?

Is Uber Really Worth More Than GM, Ford and Fiat Combined?

Johnson & Johnson Bumps Full-Year Earnings Guidance Higher After Solid Q3

Johnson & Johnson Bumps Full-Year Earnings Guidance Higher After Solid Q3

Walmart Trims 2019 Earnings Guidance After $16 Billion Flipkart Deal

Walmart Trims 2019 Earnings Guidance After $16 Billion Flipkart Deal

How to Be a Tactical Investor in the Current Market

How to Be a Tactical Investor in the Current Market